One of the weakest links in the system, the way biotech firms are financed in France, is undergoing modification.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tastemain, C. France moves to right biotech wrongs. Nat Med 2, 618 (1996). https://doi.org/10.1038/nm0696-618
Issue Date:
DOI: https://doi.org/10.1038/nm0696-618